FDA · Safety alert

FDA alerts on dosing errors involving compounded injectable semaglutide

FDA reported adverse events, including some requiring hospitalization, associated with dosing errors involving compounded injectable semaglutide and described risks tied to varying concentrations, vial-and-syringe measurement, and unit conversion.